A recent study, however, showed that NLK may play a key role in the gluconeogenesis regulatory network as a novel negative regulator of hepatic gluconeogenesis and is a potential therapeutic target for T2DM, a role that has not previously been characterized for NLK [73]. The gene discussed is NLK; the disease is type 2 diabetes mellitus.